No Takers For Biogen’s Biosimilars Business?
Firm Suggests It Could Retain Biosimilars Unit Amid Lack Of ‘Acceptable’ Offers
It’s been a year since Biogen made it clear that it was ready to put its biosimilars business on the market. But despite signaling interest in the unit from multiple potential suitors over the past 12 months, the firm says it hasn’t yet received any “acceptable” offers, and may retain it after all.
